Analysis of BCL-6 mutations in classic Hodgkin disease of the B- and T-cell type

Citation
V. Seitz et al., Analysis of BCL-6 mutations in classic Hodgkin disease of the B- and T-cell type, BLOOD, 97(8), 2001, pp. 2401-2405
Citations number
22
Categorie Soggetti
Hematology,"Cardiovascular & Hematology Research
Journal title
BLOOD
ISSN journal
00064971 → ACNP
Volume
97
Issue
8
Year of publication
2001
Pages
2401 - 2405
Database
ISI
SICI code
0006-4971(20010415)97:8<2401:AOBMIC>2.0.ZU;2-F
Abstract
BCL-6 is essential for germinal center formation and thus for affinity matu ration of immunoglobulin (Ig) genes by somatic mutations. The 5'-noncoding region of the BCL-6 gene is even a target for the mutation machinery. Trans locations of the BCL-6 gene to heterologous promoters and mutations of its 5'-noncoding regulatory region were reported to be potential mechanisms for deregulating BCL-6 expression and for playing a role in the genesis of non -Hodgkin lymphoma. In line with this hypothesis is the observation that B-c ell lymphoma with somatic mutations, such as diffuse large B-cell lymphoma and follicular lymphoma, also carry BCL-6 mutations, some of which are recu rrently detectable. Classic Hodgkin disease (cHD) is also derived from B ce lls with high loads of somatic mutations and thus a further candidate for B CL-6 mutations. To determine the presence and potential role of BCL-6 mutat ions in cHD, the 5'-noncoding BCL-6 proportion of single Hodgkin and Reed-S ternberg (HRS) cells from 6 cases of cHD and 6 cases of HD-derived cell lin es was analyzed. All B-cell-derived Ho cases and cell lines harbored BCL-6 mutations. In contrast, both T-cell-derived HD cases and cell lines were de void of BCL-6 mutations. With only one exception, there were no lymphoma-sp ecific recurrent BCL-6 mutations detected, and BCL-6 protein was absent fro m the HRS cells of most cases. In conclusion, (1) somatic BCL-6 mutations a re restricted to cHD cases of B-cell origin, and (2) the BCL-6 mutations re present mostly irrelevant somatic base substitutions without consequences f or BCL-6 protein expression and the pathogenesis of cHD. (Blood, 2001;97:24 01-2405) (C) 2001 by The American Society of Hematology.